We have located links that may give you full text access.
English Abstract
Journal Article
Review
[Thoughts about the results of the "IDEAL" study].
Orvosi Hetilap 2006 May 29
INTRODUCTION: Evidences and guidelines suggest that more intensive lowering of LDL-cholesterol will provide further benefit in coronary artery disease.
AIM AND METHOD: In the IDEAL study patients with previous myocardial infarction were randomly assigned to receive 80 mg of atorvastatin (n = 4439) or 20-40 mg simvastatin (n = 4449). The median follow-up was 4.8 years. The objective was to compare the effects of two strategies of lipid lowering therapy.
RESULTS: During treatment mean LDL-cholesterol levels were 2.7 mmol/l in the simvastatin group and 2.1 mmol/l in the atorvastatin group. A major coronary event occurred in 463 (10.4%) simvastatin patients and in 411 (9.3%) atorvastatin patients (p = 0.07). Death from any cause occurred 374 (8.4%) in the simvastatin group and 366 (8.2%) in the atorvastatin group (p = 0.81). Nonfatal acute myocardial infarction occurred 321 (7.2%) and 267 (6.0%) in the two groups (p = 0.02). Patients in the atorvastatin group had higher rates of drug discontinuation due to non-serious adverse events; transaminase elevation resulted in 43 (1.0%) versus 5 (0.1%) withdrawals (p <0.001).
CONCLUSION: Patients with high risk or very high risk may benefit from intensive lowering of LDL-cholesterol without an increase of adverse reaction but try to find the ideal statin and dose of statin.
AIM AND METHOD: In the IDEAL study patients with previous myocardial infarction were randomly assigned to receive 80 mg of atorvastatin (n = 4439) or 20-40 mg simvastatin (n = 4449). The median follow-up was 4.8 years. The objective was to compare the effects of two strategies of lipid lowering therapy.
RESULTS: During treatment mean LDL-cholesterol levels were 2.7 mmol/l in the simvastatin group and 2.1 mmol/l in the atorvastatin group. A major coronary event occurred in 463 (10.4%) simvastatin patients and in 411 (9.3%) atorvastatin patients (p = 0.07). Death from any cause occurred 374 (8.4%) in the simvastatin group and 366 (8.2%) in the atorvastatin group (p = 0.81). Nonfatal acute myocardial infarction occurred 321 (7.2%) and 267 (6.0%) in the two groups (p = 0.02). Patients in the atorvastatin group had higher rates of drug discontinuation due to non-serious adverse events; transaminase elevation resulted in 43 (1.0%) versus 5 (0.1%) withdrawals (p <0.001).
CONCLUSION: Patients with high risk or very high risk may benefit from intensive lowering of LDL-cholesterol without an increase of adverse reaction but try to find the ideal statin and dose of statin.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app